Literature DB >> 7907931

Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture.

G Defazio1, R Dal Toso, D Benvegnù, M C Minozzi, A R Cananzi, A Leon.   

Abstract

The presence of antibodies recognizing specific epitopes of dopaminergic neurons in serum of patients suffering of Parkinson's Disease (PD) as well as their capability to induce neuronal damage was investigated utilizing serum-free dissociated mesencephalic-striatal co-cultures. High affinity dopamine (DA) and GABA uptakes were assessed as specific, functional markers of dopaminergic and GABAergic cell viability, respectively. Heat-inactivated serum samples from 18 and 13 patients suffering from idiopathic and vascular parkinsonism, respectively and from 18 neurologic controls, were added to co-cultures on day 4 in vitro. Twenty four hours later, reconstituted rabbit complement was added for 60 min and uptake parameters as well as immunocytochemical staining for tyrosine hydroxylase (TH)-containing cells were subsequently assessed. DA, but not GABA, uptake was significantly decreased only when complement was added to cultures containing serum samples from 14 out of 18 patients with idiopathic parkinsonism and 3 out of 13 patients with vascular parkinsonism (Fisher test, P < 0.01). Complement addition to cultures containing serum samples from seropositive parkinsonian patients significantly reduced immunocytochemical staining of TH-containing cells. Seropositive and seronegative patients did not differ in demographic and clinical features. These results suggest that a complement-dependent humoral immune response occurs mainly in idiopathic parkinsonian patients, but its clinical relevance remains to be established.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907931     DOI: 10.1016/0006-8993(94)91541-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Autoantibodies to alpha-synuclein in inherited Parkinson's disease.

Authors:  Katerina K Papachroni; Natalia Ninkina; Angeliki Papapanagiotou; Georgios M Hadjigeorgiou; Georgia Xiromerisiou; Alexandros Papadimitriou; Anastasios Kalofoutis; Vladimir L Buchman
Journal:  J Neurochem       Date:  2007-05       Impact factor: 5.372

2.  Upregulation of glycolytic enzymes, mitochondrial dysfunction and increased cytotoxicity in glial cells treated with Alzheimer's disease plasma.

Authors:  Tharusha Jayasena; Anne Poljak; Nady Braidy; George Smythe; Mark Raftery; Mark Hill; Henry Brodaty; Julian Trollor; Nicole Kochan; Perminder Sachdev
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 3.  Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota.

Authors:  Sylvia M Dobbs; R John Dobbs; Clive Weller; André Charlett; Aisha Augustin; David Taylor; Mohammad A A Ibrahim; Ingvar Bjarnason
Journal:  J Neurovirol       Date:  2015-06-20       Impact factor: 2.643

4.  Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity.

Authors:  Matthew J Benskey; Rhyomi C Sellnow; Ivette M Sandoval; Caryl E Sortwell; Jack W Lipton; Fredric P Manfredsson
Journal:  Front Mol Neurosci       Date:  2018-02-13       Impact factor: 5.639

Review 5.  Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity.

Authors:  Vanesa Sanchez-Guajardo; Christopher J Barnum; Malú G Tansey; Marina Romero-Ramos
Journal:  ASN Neuro       Date:  2013-04-30       Impact factor: 4.146

Review 6.  Helicobacter hypothesis for idiopathic parkinsonism: before and beyond.

Authors:  R John Dobbs; Sylvia M Dobbs; Clive Weller; André Charlett; Ingvar T Bjarnason; Alan Curry; David S Ellis; Mohammad A A Ibrahim; Maria V McCrossan; John O'Donohue; Robert J Owen; Norman L Oxlade; Ashley B Price; Jeremy D Sanderson; Malur Sudhanva; John Williams
Journal:  Helicobacter       Date:  2008-10       Impact factor: 5.753

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.